Bengaluru, Karnataka, India, October 2025 — Vivek V. Kamath has been appointed as the new Chief Executive Officer at PlasmaGen BioSciences (P) Ltd, marking a significant leadership addition to India’s pioneering plasma protein therapeutics company. In his new role, Vivek will lead the organization’s growth agenda, strengthen operational excellence, and further the mission of bridging the demand–supply gap for plasma-derived medicinal products in India.
Vivek brings with him more than two decades of diverse leadership experience in the healthcare and pharmaceutical sectors. Most recently, he served as Senior Advisor at TPG, providing strategic counsel to global healthcare initiatives, and as Senior Advisor at Lighthouse Funds, guiding portfolio companies on growth and transformation strategies.
Prior to that, he was Managing Director & General Manager at Abbott India Limited, where he played a pivotal role in strengthening Abbott’s presence in India’s healthcare market. Before this, he successfully led MSD in India as Managing Director, following earlier senior roles within the company, where he oversaw cardiovascular, metabolic, and market access businesses.
Earlier in his career, Vivek held leadership positions at Roche Diagnostics as Regional Head – India & Neighboring Countries and at Novartis (Singapore) Pte Ltd as Regional Head – ASEAN, managing complex multi-country portfolios across Asia. His leadership journey also includes impactful roles at Ranbaxy Global Consumer Health, Pfizer, and Parke-Davis, where he drove growth, innovation, and organizational transformation.
With this appointment, PlasmaGen BioSciences reinforces its commitment to advancing plasma protein therapeutics in India and delivering on its vision of improving healthcare access and outcomes for patients with rare and genetic diseases.
About PlasmaGen BioSciences (P) Ltd
PlasmaGen BioSciences Private Limited, established in 2010 in Bengaluru, is India’s first plasma protein therapeutics-focused company. Committed to bridging the gap between the demand and supply of plasma protein products, PlasmaGen works towards enhancing the health and quality of life of thousands of patients across the country. The company is actively engaged in creating awareness about rare and genetic diseases such as Hemophilia, Thalassemia, Sickle-cell anemia, and Primary Immunodeficiencies. With its upcoming state-of-the-art manufacturing facility at Kolar, PlasmaGen is moving closer to making India self-reliant in plasma-derived medicinal products.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
